Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments

by Juha J. Hulmi, Tuuli A. Nissinen, Fabio Penna, Andrea Bonetto
Published 2021-02-01

Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota—A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?

by Satu Pekkala, Anniina Keskitalo, Emilia Kettunen, Sanna Lensu, Noora Nykänen, Teijo Kuopio, Olli Ritvos, Jaakko Hentilä, Tuuli A. Nissinen, Juha J. Hulmi
Published 2019-11-01

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses

by Tuuli A. Nissinen, Jaakko Hentilä, Fabio Penna, Anita Lampinen, Juulia H. Lautaoja, Vasco Fachada, Tanja Holopainen, Olli Ritvos, Riikka Kivelä, Juha J. Hulmi
Published 2018-06-01

Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver

by Jaakko Hentilä, Tuuli A. Nissinen, Ayhan Korkmaz, Sanna Lensu, Mika Silvennoinen, Arja Pasternack, Olli Ritvos, Mustafa Atalay, Juha J. Hulmi, Juha J. Hulmi
Published 2019-01-01

Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle

by Juha J. Hulmi, Tuuli A. Nissinen, Markus Räsänen, Joni Degerman, Juulia H. Lautaoja, Karthik Amudhala Hemanthakumar, Janne T. Backman, Olli Ritvos, Mika Silvennoinen, Riikka Kivelä
Published 2018-04-01